Research Overview Sample Clauses

Research Overview. Promptly after the Effective Date, the Parties shall meet to discuss the effective launch of the R&D Collaboration (including the identification of early R&D Activities, especially the first Lead Compound(s) for which research and development is to be

Research Overview. Pursuant to this Agreement and as further provided in this ARTICLE 3, MacroGenics and Gilead shall use Reasonable Research Efforts to conduct the Research activities assigned to such Party in each Research Plan during each Research Term for each Research Program. MacroGenics and Gilead shall conduct each Research Program in a good scientific manner and in accordance with applicable Law, including GLP and GCP. Neither Party warrants that any Research Program shall achieve any of the research objectives contemplated in its Research Plan. At the end of the applicable Research Term, each Party’s obligation to conduct such Research Program shall cease unless the Parties mutually agree to extend its Research Term.

Research Overview. Archemix will conduct Research in the Field in accordance with an approved Research Plan to generate Candidate Compounds during the Research Program Term. The Parties will prepare a Research Plan for Nuvelo’s approval for the initial twelve (12) months of the Research Program Term within sixty (60) days of the Effective Date. For the second and third years of the Research Program Term the Parties shall prepare an updated Research Plan for discussion by the JMC and approval by Nuvelo at least ninety (90) days prior to the first and second anniversaries of the Effective Date. Each Research Plan will include, without limitation, (a) a prioritized list of the Coagulation Cascade Protein targets for which Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. Archemix will generate Aptamers; (b) a target product profile for Short Acting Coagulation Cascade Aptamers to meet for each Coagulation Cascade Protein pursued so that such Aptamers can be considered as Candidate Compounds; and (c) a proposed work plan and resource allocation plan.

Research Overview. Commencing on the Effective Date, the Parties will each use Diligent Efforts to conduct the Research Program on a collaborative basis and in accordance with this Agreement, with the goal of discovering, identifying, synthesizing and performing preclinical research on Active Compounds, and with the further goal of identifying and selecting certain Active Compounds that are suitable for clinical development by J&J as Development Compounds and, if Regulatory Approval is obtained, for commercialization by J&J as Collaboration Products as soon as reasonably practicable. The Parties will conduct the Research Program in accordance with the Research Plan (as amended or revised by the JRC from time to time) and subject to the oversight of the JSC. The Research Plan, among other things as further specified in Section 2.6, will specify the scientific direction and research activities, and allocate Research Program responsibilities and resources between the Parties in a manner consistent with this Agreement.

Research Overview. Archemix will conduct Research in the Field in accordance with an approved Research Plan to generate Candidate Compounds during the Research Program Term. The Parties will prepare a Research Plan for Nuvelo’s approval for the initial twelve (12) months of the Research Program Term within sixty (60) days of the Effective Date. For the second and third years of the Research Program Term the Parties shall prepare an updated Research Plan for discussion by the JMC and approval by Nuvelo at least ninety (90) days prior to the first and second anniversaries of the Effective Date. Each Research Plan will include, without limitation, (a) a prioritized list of the Coagulation Cascade Protein targets for which Archemix will generate Aptamers; (b) a target product profile for Short Acting Coagulation Cascade Aptamers to meet for each Coagulation Cascade Protein pursued so that such Aptamers can be considered as Candidate Compounds; and (c) a proposed work plan and resource allocation plan.

Research Overview. On a Collaboration Program-by-Collaboration Program basis, Company (directly or through its Affiliates or Subcontractors) will use Commercially Reasonable Efforts to perform the Research Activities for such Collaboration Program, for the purpose of generating Development Candidate(s) directed against the applicable Collaboration Target in accordance with the Research Plan. The Parties acknowledge that each Collaboration Program could result in the identification of no Development Candidate(s) for such Collaboration Program or multiple Development Candidates for such Collaboration Program.

Research Overview. The main objective of this research was to evaluate the use of NBI condition ratings to study concrete bridge deck performance. This research was subdivided into four subtasks. Subtask 1 included an in- depth literature review of reported research on concrete bridge deck durability and service-life models. In Subtask 2, key parameters found to influence durability were identified in the literature. Subtask 3 summarizes the capabilities and limitations of two service-life prediction software packages. As part of Subtask 4, a nationwide database was created that includes identified parameters and two perfor- ▇▇▇▇▇ parameters were computed: time-in-condition rating (TICR) and deterioration rate (DR). Two analyses were implemented and evaluated to study the relationship between influence and perfor- ▇▇▇▇▇ parameters: binary logistic regression and Bayesian survival analysis. Please see the internal final report for details regarding all aspects of the work performed (Ghonima et al., 2018). Bayesian survival analysis is highlighted in this Technical Brief (see Section “Data Analysis”) as it was found most practical and useful for an owner or agency to study concrete bridge deck perfor- ▇▇▇▇▇. Background‌

Research Overview. On a Collaboration Program-by-Collaboration Program basis, in accordance with the terms and conditions of this Agreement, Company will use Commercially Reasonable Efforts to perform the activities set forth in the Research Plan for such Collaboration Program for the purpose of generating Candidate Drug(s) directed against the applicable Collaboration Target for Vertex to advance through Clinical Trials and bring to patients as commercial products in the Field following its Option Exercise with respect to the applicable Collaboration Target. The Parties acknowledge that the Collaboration Programs could result in the identification of no Candidate Drug(s) for a given Collaboration Program or multiple Candidate Drugs for such Collaboration Program.

Research Overview. Given the depth of the complexity of local initiatives to recruit businesses, my research takes a focused, comparative case-study approach. While there are definitely benefits to an additional quantitative analysis of overall trends in development efforts and spending, the complexity and shoddiness of data renders cross-state—and even within-state—data incommensurable. Moreover, the questions posed above are not simply about overall trends, but directed at the changing processes and relations between governments and businesses. These factors point towards a qualitative, case- oriented research design. This view was confirmed in a personal correspondence with Dr.